Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      If you purchased Theranos blood testing services, including at a Walgreens store, a class action lawsuit may affect your rights


      News provided by

      JND Legal Administration

      Jul 14, 2022, 09:24 ET

      Share this article

      Share this article


      SEATTLE, July 14, 2022 /PRNewswire/ -- JND Legal Administration announces a class action lawsuit in the U.S. District Court for the District of Arizona against Defendants Theranos, Inc., Walgreens Boots Alliance, Inc. and Walgreen Arizona Drug Company (together called "Walgreens"), Elizabeth Holmes, and Ramesh Balwani (collectively, "Defendants"). The lawsuit is called In re Arizona Theranos, Inc., Litigation, Case No. 2:16-cv-2138-DGC. 

      This notice does not imply that there has been any violation of law or wrongdoing by Defendants or that there will be recovery after trial. Defendants contend that they did not do anything wrong, and they are not liable for any harm alleged by the Plaintiffs. There is no money available now, and there is no guarantee that there will be.  Even if money does become available, you will not be allowed to recover for any amounts that Defendants have already paid you. However, your legal rights may be affected, and you may have a choice to make now.

      What is this lawsuit about?  The claims in the lawsuit arise out of Theranos blood testing services offered in Walgreens and Theranos stores. The lawsuit claims, among other things, that these blood testing services were not capable of producing reliable results, that the Defendants concealed the blood testing services' unreliability, that Walgreens knew that the blood testing services were unreliable and not market-ready, that the Defendants conspired to commit fraud on consumers, that Theranos's "tiny" blood testing technology (blood drawn with fingerpricks) was still in development, and that the customers who were subject to "tiny" Theranos blood draws by Walgreens employees gave their consent to those blood draws under false pretenses.

      The Defendants deny these claims. Walgreens maintains it did not know that Theranos's blood testing services "were unreliable and not market-ready," and that it therefore did not conspire to commit fraud on consumers. Walgreens further maintains that it was, in fact, a victim of Theranos's fraud. Holmes and Balwani, on the other hand, contend that Theranos's test results were generally accurate and reliable, and that consumers were neither deceived nor injured. Defendants also assert that most class members have already been fully reimbursed for amounts paid for the tests through the Arizona Attorney General Consent Decree or otherwise, and so no other recovery is necessary or available to those class members. Plaintiffs claim that some class members have not been refunded or fully refunded for the tests and that other damages, beyond refunds for the tests, are due to class members.

      The Court has not decided whether the Defendants have done anything wrong. That will not happen until the trial. The Court appointed two law firms―Lieff Cabraser Heimann & Bernstein LLP and Keller Rohrback LLP―as "Class Counsel" to represent the Class and Subclasses.

      This lawsuit does not seek damages or other relief for personal injury, emotional distress, retesting costs, or medical care costs. If you wish to pursue any of that relief, you need to exclude yourself ("opt out") from this lawsuit. 

      More information about the claims in this case can be found in the operative Second Amended Complaint and in other key case documents which may be viewed at www.TheranosLawsuit.com.

      Am I part of the Class?  The Court has certified a Class and three Subclasses. You are in the Class and/or the Subclasses if you fit within the definition(s) below: 

      Class: All purchasers of Theranos testing services, including consumers who paid out-of-pocket, through health insurance, or through any other collateral source between November 2013 and June 2016.

      Arizona Subclass: All purchasers of Theranos testing services in Arizona between November 2013 and June 2016.

      California Subclass: All purchasers of Theranos testing services in California, between September 2013 and June 2016.

      Walgreens Edison Subclass: All purchasers of Theranos testing services who were subjected to "tiny" blood draws (fingerpricks) by a Walgreens employee between November 2013 and March 2015.

      What are my options?  If you are a class member, you have the option to do nothing or exclude yourself.

      Do Nothing:  If you do nothing, you remain a member of the Class and/or Subclasses, and are therefore bound by the outcome of the lawsuit regardless of who wins.

      If Defendants are found liable, you may get money or benefits that may come from the lawsuit.

      If Defendants are not found liable, you will receive no benefits, you give up any right to sue Defendants on your own about the same legal claims in this lawsuit, and will be bound by the result of this lawsuit.

      Exclude Yourself ("Opt Out"):  If you ask to be excluded from this lawsuit, and money or benefits are later awarded, you will not share in the money or benefits.  If you ask to be excluded from this lawsuit, you will keep your right to hire your own lawyer to sue Defendants on your own about the same legal claims in this lawsuit.

      If you ask to be excluded, you will not be bound by the results of any trial of the Class Action, and also not entitled to any damages (money or benefits), if any, that are later awarded. The deadline to request exclusion is SEPTEMBER 12, 2022.

      For details about your rights and options and how to exclude yourself, go to www.TheranosLawsuit.com.

      When is the trial?  The Court has not yet scheduled the trial in this case, but it is expected that the trial will occur in 2023, and will take place in the United States District Court Courthouse, 401 W. Washington, Phoenix, AZ 85003. Once the trial is scheduled, the date and location will be posted on www.TheranosLawsuit.com. You do not need to attend any trial. Class Counsel will present the case for the Plaintiffs and the Class and Subclasses, and lawyers for Defendants will present on their behalf. If there is a trial, you or your own lawyer is welcome to attend at your own expense.

      How do I get more information?  For additional information, to review key case documents, and to register for case updates, visit www.TheranosLawsuit.com. You can also get more information by calling the Administrator toll-free at 1-866-615-0978, contacting Class Counsel (for their contact information visit www.TheranosLawsuit.com), or writing the Administrator via email at [email protected] or by mail at: In re Arizona Theranos, Inc., Litigation, c/o JND Legal Administration, P.O. Box 91214, Seattle, WA 98111.

      PLEASE DO NOT CONTACT THE COURT REGARDING THIS NOTICE.

      SOURCE JND Legal Administration

      Modal title

      Also from this source

      Notice of Pendency and Proposed Settlement Involving All Record and Beneficial Holders of dMY Technology Group, Inc. IV ("dMY IV") Class A Common Stock Between December 1, 2021 and December 7, 2021

      /JND Legal Administration-- IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE JULIO MONTEALEGRE and HARRY TRAN, individually on behalf of themselves...

      Johnson Van Kwawegen LLP, Block & Leviton LLP, Labaton Keller Sucharow LLP, and Bernstein Litowitz Berger & Grossmann LLP Announce Notice of Pendency and Proposed Settlement Involving Record Holders and Beneficial Owners of Thoughtworks Holding, Inc. Common Stock

      JND Legal Administration-- IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE THOUGHTWORKS HOLDING, INC. Consolidated C.A. No. 2024-1295-BWD...

      More Releases From This Source

      Explore

      Banking & Financial Services

      Banking & Financial Services

      Hispanic

      Hispanic

      Diversity, Equity & Inclusion

      Diversity, Equity & Inclusion

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.